AEROVATE THERAPEUTICS
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
AEROVATE THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aerovatetx.com
Total Employee:
11+
Status:
Active
Contact:
+1 617 778 2494
Email Addresses:
[email protected]
Total Funding:
72.6 M USD
Technology used in webpage:
IPv6 COVID-19 Akamai Hosted
Similar Organizations
Ajax Therapeutics
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Ardeagen
Ardeagen is a biotechnology company that conducts research and development of drugs and antibodies for cancer.
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Surveyor Capital
Surveyor Capital investment in Series A - Aerovate Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Aerovate Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Aerovate Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series A - Aerovate Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Aerovate Therapeutics
RA Capital Management
RA Capital Management investment in Seed Round - Aerovate Therapeutics
Official Site Inspections
http://www.aerovatetx.com Semrush global rank: 2.88 M Semrush visits lastest month: 5.68 K
- Host name: 241.121.134.34.bc.googleusercontent.com
- IP address: 34.134.121.241
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Aerovate Therapeutics"
About Us - Aerovate Therapeutics
He also serves on the Boards of Blueprint Medicines Corporation, Day One Biopharmaceuticals, Inc., and PepGen Inc. and is a part-time Venture Partner at RA Capital Management, L.P., having previously also served as a member of โฆSee details»
Aerovate Therapeutics, Inc. | LinkedIn
Aerovate Therapeutics, Inc. | 4,271 followers on LinkedIn. Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with ...See details»
Investors - Aerovate Therapeutics
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease.See details»
Aerovate Therapeutics - Crunchbase Company Profile โฆ
Contact Email [email protected] Phone Number +1 617 778 2494 Aerovate Therapeutics is a biotechnology company focused on developing drugs that โฆSee details»
Aerovate Therapeutics, Inc. Management Team | Org Chart
Aerovate Therapeutics, Inc. employs 47 employees. The Aerovate Therapeutics, Inc. management team includes Timothy Noyes (Chief Executive Officer), George Eldridge (Chief โฆSee details»
Aerovate Therapeutics, Inc. (AVTE) Company Profile & Overview
Jun 30, 2021 930 Winter Street, Suite M-500 Waltham, Massachusetts 02451 United StatesSee details»
Aerovate Therapeutics - Overview, News & Similar companies
May 15, 2024 View Aerovate Therapeutics (www.aerovatetx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well โฆSee details»
Aerovate Therapeutics - VentureRadar
Website: https://www.aerovatetx.com/ Develops inhaled therapies for pulmonary arterial hypertension, including an innovative treatment utilizing imatinib, aiming to ...See details»
Aerovate Therapeutics - businessabc
Mar 28, 2025 Aerovate Therapeutics was founded in 2015 with the mission of developing highly effective aerosolized inhaler solutions for the inhaled treatment of respiratory diseases such as โฆSee details»
Aerovate Therapeutics - Company Profile - Tracxn
Jan 28, 2025 Aerovate Therapeutics - Developer of therapeutic solutions for pulmonary arterial hypertension. Public Company. Raised a total funding of $75.8M over 1 round from 3 โฆSee details»
Contact Us - Aerovate Therapeutics
Have questions about our programs or want to learn more about Aerovate? Please get in touch with us. [email protected] 617-443-2400 930 Winter StreetSee details»
Aerovate Therapeutics Inc. - Cruelty Free Investing
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs that improve the lives of patients with rare cardiopulmonary โฆSee details»
Aerovate Therapeutics Appoints Timothy Noyes as Chief Executive โฆ
Aerovate has completed a Phase 1 study in healthy volunteers and AV-101 was generally well-tolerated with no serious adverse events reported. For more information, please visit โฆSee details»
Organization: Aerovate Therapeutics - Cbonds.com
Organization name. Aerovate Therapeutics Inc. Country name. USA Country of registration. USA. Industry. Pharmaceutical Preparation and Biotechnology. Bond debt - ...See details»
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 โฆSee details»
Press Release - ir.aerovatetx.com
Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share. WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today โฆSee details»
Join Us - Aerovate Therapeutics
The Aerovate team is a diverse group of researchers and professionals dedicated to make a meaningful impact for people living with cardiopulmonary disease.See details»
Aerovate
Inspiring tomorrow's scientists & entrepreneurs through competition. Building a community of lifelong learners!See details»
Programs - Aerovate Therapeutics
May 16, 2024 Targeting Disease Drivers Aerovateโs lead program, AV-101, a dry powder inhaled formulation of imatinib, being investigated in pulmonary arterial hypertension (PAH), directly โฆSee details»
Senior Manager / Associate Director, Payroll (temp to perm)
The Senior Manager / Associate Director, Payroll (temp to perm) will oversee and supervise the organization's payroll functions, ensuring pay is processed on time, accurately, and in โฆSee details»